septemb
inform
uk
case
acut
respiratori
syndrom
renal
failur
patient
travel
histori
kingdom
saudi
arabia
yearold
saudi
nation
die
similar
diseas
earlier
caus
pathogen
novel
human
betacoronaviru
hcovemc
quickli
identifi
sputum
sampl
earlier
case
gene
sequenc
viru
ident
viru
isol
clinic
sampl
later
case
outbreak
hcovemc
infect
saudi
arabia
rais
great
concern
potenti
pandem
sarslik
diseas
strategi
combat
newli
emerg
infecti
diseas
prepar
believ
exist
sar
research
may
provid
use
templat
develop
vaccin
therapeut
hcovemc
infect
far
effect
antisar
vaccin
therapeut
well
develop
apart
financi
support
anoth
main
challeng
clinic
develop
antisar
vaccin
lack
endem
sar
lethal
natur
diseas
sar
caus
sar
coronaviru
sarscov
emerg
china
caus
nearli
case
death
outbreak
although
sar
current
control
possibl
new
sar
outbreak
remain
global
concern
potenti
zoonot
transmiss
sarscov
sarscovlik
virus
natur
host
human
accident
intent
releas
laboratori
sarscov
strain
therefor
develop
vaccin
therapeut
prevent
treatment
sar
still
matter
urgenc
global
sar
pandem
mani
foundat
pharmaceut
compani
govern
provid
abund
fund
support
develop
antisar
vaccin
therapeut
howev
disappear
sar
fund
either
withdrawn
discontinu
lack
sustain
market
product
develop
number
inactiv
liveattenu
sar
vaccin
well
base
vector
encod
fulllength
protein
sarscov
show
high
immunogen
induc
neutral
antibodi
respons
protect
sarscov
challeng
howev
vaccin
candid
may
also
induc
immunopatholog
harm
immun
respons
rais
concern
safeti
hand
recombin
protein
contain
receptorbind
domain
sarscov
protein
could
develop
safe
effect
sar
vaccin
potenti
base
abil
receptor
bind
domainbas
vaccin
induc
stronger
crossneutr
antibodi
respons
protect
sarscov
correspondingli
lower
probabl
induc
immunopatholog
contrast
sar
vaccin
candid
mention
previous
far
specif
antisar
drug
develop
number
drug
candid
includ
sarscov
fusion
inhibitor
proteinas
eg
cystein
proteinas
inhibitor
plpro
inhibitor
rnadepend
rna
polymeras
inhibitor
helicas
inhibitor
sirna
inhibit
sarscov
structur
protein
e
n
therapeut
antibodi
develop
laboratori
preclin
studi
howev
develop
sar
vaccin
therapeut
still
need
combat
newli
emerg
infecti
diseas
prepar
futur
scienc
group
none
forward
clinic
trial
possibl
reason
previous
describ
vaccin
develop
apart
financi
support
anoth
main
challeng
clinic
develop
antisar
vaccin
lack
endem
sar
lethal
natur
diseas
ethic
conduct
human
efficaci
studi
expos
healthi
human
volunt
lethal
agent
like
sarscov
fortun
howev
accord
anim
rule
pivot
anim
efficaci
studi
conduct
evalu
vivo
efficaci
antisar
vaccin
use
two
anim
speci
exhibit
pathophysiolog
diseas
host
immun
respons
close
match
human
data
anim
experi
consid
us
fda
evid
effect
test
vaccin
author
relev
affili
financi
involv
organ
entiti
financi
interest
financi
conflict
subject
matter
materi
discuss
manuscript
includ
employ
consult
honoraria
stock
ownership
option
expert
testimoni
grant
patent
receiv
pend
royalti
write
assist
util
product
manuscript
